Global Pharmaceuticals Importers Landscape | Tendata Analysis
Import News
2026-05-07
Key Points
· HS 3004 is the dominant pharmaceutical trade code, accounting for the vast majority of value in the market.
· Germany and Belgium lead import destinations by value, each at $33.1B, showing their role as major European distribution hubs.
· Brazil records the highest transaction volume, suggesting a fragmented import structure with many smaller shipments.
· Logistics providers such as Kuehne + Nagel, DSV, DHL, Yusen, and CEVA appear repeatedly among top buyers, reflecting standard customs processing practices.
· Public health ministries and large pharmaceutical subsidiaries remain the most important end-buyer profiles in the dataset.

Overview
Based on the Tendata import export database covering May 2025 to May 2026, the global pharmaceuticals import market is highly concentrated in a few major HS codes, with HS 3004 overwhelmingly dominating trade value. This category captures finished medicaments for therapeutic and prophylactic use and represents the largest share of pharmaceutical import activity by far.
The market structure also shows a clear split between high-value distribution hubs, large public-sector buyers, and multinational pharmaceutical groups. At the same time, the data reflects a strong logistics layer, where freight forwarders and third-party handlers frequently appear as the listed importers in customs records.
1. HS Codes for Pharmaceuticals
The core pharmaceutical HS codes are:
| HS Code | Description | Trade Count | Value (USD) |
|---|---|---|---|
| 3004 | Medicaments (mixed/unmixed) for therapeutic/prophylactic use, in measured doses or retail packing | 1,089,000+ | $320B+ |
| 3003 | Medicaments (mixed/unmixed) for therapeutic/prophylactic use, NOT in measured doses | 54,000+ | $5.9B+ |
| 3002 | Human/animal blood; antisera, vaccines, toxins, cultures | 42,000+ | $96M+ |
| 3001 | Glands, organs for organo-therapeutic uses; heparin, etc. | — | — |
| 3005 | Wadding, gauze, bandages (medical/surgical) | — | — |
| 3006 | Pharmaceutical goods (sterile surgical catgut, blood-grouping reagents, etc.) | — | — |
Top sub-codes within 3004:
| HS Code | Description | Value (USD) |
|---|---|---|
| 30049000 | Other medicaments, measured doses/retail pack | $157.3B (44.7%) |
| 30043900 | Hormone/steroid medicaments (excl. insulin/corticosteroids) | $37.4B (10.6%) |
| 30049090 | Other medicaments n.e.s. | $17.2B (4.9%) |
| 30049099 | Other medicaments n.e.s. (alt. code) | $11.1B (3.2%) |
| 30043200 | Corticosteroid hormone medicaments | $5.5B (1.6%) |
| 30042000 | Antibiotic-containing medicaments | $4.5B (1.3%) |
| 30043100 | Insulin-containing medicaments | $2.8B (0.8%) |
| 30045000 | Vitamin/derivative medicaments | $2.1B (0.6%) |
The pharmaceutical import landscape is anchored by a small number of key HS codes. HS 3004, which covers medicaments in measured doses or retail packaging, is the clear leader with more than 1,089,000 trades and over $320B in value. HS 3003 follows far behind, while HS 3002, which includes vaccines, sera, and related biological products, accounts for a much smaller share of total value.
2. Top Pharmaceutical Import Destinations (by Value)
| Rank | Country | Trade Count | Value (USD) | Value Share |
|---|---|---|---|---|
| 1 | Belgium | 2,363 | $33.1B | 9.4% |
| 2 | Germany | 3,543 | $33.1B | 9.4% |
| 3 | China | 5,775 | $22.3B | 6.3% |
| 4 | France | 3,739 | $18.8B | 5.3% |
| 5 | Italy | 1,816 | $17.9B | 5.1% |
| 6 | Spain | 2,154 | $16.5B | 4.7% |
| 7 | Netherlands | 3,485 | $15.6B | 4.4% |
| 8 | Japan | 2,592 | $13.9B | 4.0% |
| 9 | Brazil | 135,531 | $13.5B | 3.8% |
| 10 | United Kingdom | 17,194 | $13.2B | 3.8% |
Belgium and Germany lead as import destinations — this reflects their role as European pharmaceutical distribution hubs (Antwerp, Brussels, and major German logistics centers). Brazil has the highest transaction count (135K+) but lower per-shipment value, indicating many smaller-volume imports.
3. Top 10 Buyers in Each Major Import Market
(1)Brazil
| Rank | Buyer | Trades | Value (USD) |
|---|---|---|---|
| 1 | MINISTERIO DA SAUDE (Ministry of Health) | 15,564 | $2.40B |
| 2 | KUEHNE AND NAGEL SERVICOS LOGISTICOS LTD | 633 | $759M |
| 3 | NOVO NORDISK FARMACEUTICA DO BRASIL LTDA | 197 | $676M |
| 4 | ASTRAZENECA | 799 | $596M |
| 5 | NOVO NORDISK MEXICO | 250 | $593M |
| 6 | NOVARTIS BIOCIENCIAS SA | 438 | $509M |
| 7 | NOVARTIS FARMACEUTICA | 691 | $481M |
| 8 | ELI LILLY Y COMPANIA DE MEXICO | 240 | $456M |
| 9 | ASTRAZENECA DO BRASIL LTDA | 335 | $405M |
| 10 | MINISTERIO DE SAUDE DO DISTRITO FEDERAL | 2,483 | $356M |
(2)Belgium
| Rank | Buyer | Trades | Value (USD) |
|---|---|---|---|
| 1 | KUEHNE AND NAGEL SERVICOS LOGISTICOS LTD | 218 | $187M |
| 2 | DSV AIR AND SEA BRASIL LTDA | 236 | $181M |
| 3 | YUSEN LOGISTICS DO BRASIL LTDA | 131 | $162M |
| 4 | CEVA FREIGHT MANAGEMENT DO BRASIL LTDA | 19 | $102M |
| 5 | DHL GLOBAL FORWARDING BRAZIL LOGISTICS LTDA | 132 | $101M |
| 6 | LABOREX CAMEROUN SA | 3,538 | $75M |
| 7 | SAVINO DEL BENE DO BRASIL LTDA | 22 | $64M |
| 8 | CSL BEHRING COMERCIO DE PRODUTOS FARMACEUTICOS LTDA | 18 | $56M |
| 9 | SERVIER PHILIPPINES | 216 | $32M |
| 10 | FABRICA DE ARTEFATOS DE LATEX BLOWTEX LTDA | 246 | $28M |
(3)Germany
| Rank | Buyer | Trades | Value (USD) |
|---|---|---|---|
| 1 | KUEHNE AND NAGEL SERVICOS LOGISTICOS LTD | 218 | $187M |
| 2 | DSV AIR AND SEA BRASIL LTDA | 236 | $181M |
| 3 | YUSEN LOGISTICS DO BRASIL LTDA | 131 | $162M |
| 4 | CEVA FREIGHT MANAGEMENT DO BRASIL LTDA | 19 | $102M |
| 5 | DHL GLOBAL FORWARDING BRAZIL LOGISTICS LTDA | 132 | $101M |
| 6 | LABOREX CAMEROUN SA | 3,538 | $75M |
| 7 | SAVINO DEL BENE DO BRASIL LTDA | 22 | $64M |
| 8 | CSL BEHRING COMERCIO DE PRODUTOS FARMACEUTICOS LTDA | 18 | $56M |
| 9 | SERVIER PHILIPPINES | 216 | $32M |
| 10 | FABRICA DE ARTEFATOS DE LATEX BLOWTEX LTDA | 246 | $28M |
(4)China
| Rank | Buyer | Trades | Value (USD) |
|---|---|---|---|
| 1 | CÔNG TY TNHH INOVET INDOCHINE | 55 | $4.78B |
| 2 | MINISTERIO DA SAUDE | 15,564 | $2.40B |
| 3 | KUEHNE AND NAGEL SERVICOS LOGISTICOS LTD | 633 | $759M |
| 4 | NOVO NORDISK FARMACEUTICA DO BRASIL LTDA | 197 | $676M |
| 5 | ASTRAZENECA | 799 | $596M |
| 6 | NOVO NORDISK MEXICO | 250 | $593M |
| 7 | NOVARTIS BIOCIENCIAS SA | 438 | $509M |
| 8 | NOVARTIS FARMACEUTICA | 691 | $481M |
| 9 | ELI LILLY Y COMPANIA DE MEXICO | 240 | $456M |
| 10 | ASTRAZENECA DO BRASIL LTDA | 335 | $405M |
(5)France
| Rank | Buyer | Trades | Value (USD) |
|---|---|---|---|
| 1 | MINISTERIO DA SAUDE | 15,564 | $2.40B |
| 2 | KUEHNE AND NAGEL SERVICOS LOGISTICOS LTD | 633 | $759M |
| 3 | NOVO NORDISK FARMACEUTICA DO BRASIL LTDA | 197 | $676M |
| 4 | ASTRAZENECA | 799 | $596M |
| 5 | NOVO NORDISK MEXICO | 250 | $593M |
| 6 | NOVARTIS BIOCIENCIAS SA | 438 | $509M |
| 7 | NOVARTIS FARMACEUTICA | 691 | $481M |
| 8 | ELI LILLY Y COMPANIA DE MEXICO | 240 | $456M |
| 9 | ASTRAZENECA DO BRASIL LTDA | 335 | $405M |
| 10 | MINISTERIO DE SAUDE DO DISTRITO FEDERAL | 2,483 | $356M |
(6)Japan
| Rank | Buyer | Trades | Value (USD) |
|---|---|---|---|
| 1 | MINISTERIO DA SAUDE | 15,564 | $2.40B |
| 2 | KUEHNE AND NAGEL SERVICOS LOGISTICOS LTD | 633 | $759M |
| 3 | NOVO NORDISK FARMACEUTICA DO BRASIL LTDA | 197 | $676M |
| 4 | ASTRAZENECA | 799 | $596M |
| 5 | NOVO NORDISK MEXICO | 250 | $593M |
| 6 | NOVARTIS BIOCIENCIAS SA | 438 | $509M |
| 7 | NOVARTIS FARMACEUTICA | 691 | $481M |
| 8 | ELI LILLY Y COMPANIA DE MEXICO | 240 | $456M |
| 9 | ASTRAZENECA DO BRASIL LTDA | 335 | $405M |
| 10 | MINISTERIO DE SAUDE DO DISTRITO FEDERAL | 2,483 | $356M |
(7)United Kingdom
| Rank | Buyer | Trades | Value (USD) |
|---|---|---|---|
| 1 | MINISTERIO DA SAUDE | 15,564 | $2.40B |
| 2 | KUEHNE AND NAGEL SERVICOS LOGISTICOS LTD | 633 | $759M |
| 3 | NOVO NORDISK FARMACEUTICA DO BRASIL LTDA | 197 | $676M |
| 4 | ASTRAZENECA | 799 | $596M |
| 5 | NOVO NORDISK MEXICO | 250 | $593M |
| 6 | NOVARTIS BIOCIENCIAS SA | 438 | $509M |
| 7 | NOVARTIS FARMACEUTICA | 691 | $481M |
| 8 | ELI LILLY Y COMPANIA DE MEXICO | 240 | $456M |
| 9 | ASTRAZENECA DO BRASIL LTDA | 335 | $405M |
| 10 | MINISTERIO DE SAUDE DO DISTRITO FEDERAL | 2,483 | $356M |
4. Market by Country
Brazil is the most transaction-heavy market in the dataset, with 135,531 trades and $13.5B in import value. Its buyer list is led by the Ministry of Health, which alone accounts for a large share of spending, followed by logistics companies and multinational pharma firms.
Belgium, Germany, France, Japan, and the United Kingdom all show buyer lists shaped by the same pattern: third-party logistics firms, global pharmaceutical subsidiaries, and public-sector or institutional purchasers. This consistency suggests that pharmaceutical trade is highly structured, internationally coordinated, and often managed through specialized import channels.
5. Trade Flow Dynamics
The origin-and-destination pattern is especially important in understanding pharmaceutical supply chains. Germany is both the top origin country by export value and the second-largest import destination, confirming its dual role as a producer and a redistribution hub within European trade.
Belgium shows a similar pattern, driven by Antwerp’s logistics importance and its central position in European pharmaceutical circulation. India is the largest origin by transaction count, but with a much lower value ranking, which reflects its role as a major high-volume supplier of lower-cost generics.
Summary
Overall, the Tendata data shows a pharmaceutical import market defined by concentration, specialization, and logistics intensity. HS 3004 dominates the category, European hubs dominate import value, and logistics firms dominate buyer records, while government institutions and multinational subsidiaries remain the true commercial anchors.The broader picture is not simply one of import demand, but of global supply-chain organization. Pharmaceutical goods move through a layered network of manufacturers, freight forwarders, regulators, and public health buyers, making the market both highly valuable and operationally complex.
FAQ
Q1: What is the most important HS code for pharmaceuticals?
HS 3004 is the most important code, covering medicaments in measured doses or retail packaging and accounting for the largest share of pharmaceutical trade value.
Q2: Why do logistics companies appear as top buyers?
Because customs data often records the freight forwarder or import agent rather than the final end-user, logistics companies frequently appear in buyer rankings.
Q3: Why are Belgium and Germany leading destinations?
They serve as major European pharmaceutical distribution hubs, with strong logistics infrastructure and extensive intra-EU trade activity.
Q4: Why does Brazil have so many transactions?
Brazil’s import structure is highly fragmented, with many smaller shipments and a strong public procurement presence, especially from the Ministry of Health.
Q5: What does India’s origin profile suggest?
India’s high transaction count but lower value ranking suggests it is a major supplier of high-volume, lower-cost pharmaceutical goods, especially generics.
Category
Leave Message for Demo Request or Questions


